MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 147.79 Billion KRW | 9.33% |
| 2022 | 135.18 Billion KRW | -1.61% |
| 2021 | 137.38 Billion KRW | -9.76% |
| 2020 | 152.25 Billion KRW | -17.37% |
| 2019 | 184.24 Billion KRW | 22.83% |
| 2018 | 150 Billion KRW | 12.48% |
| 2017 | 133.35 Billion KRW | 5.51% |
| 2016 | 126.39 Billion KRW | -4.46% |
| 2015 | 132.29 Billion KRW | 12.59% |
| 2014 | 117.5 Billion KRW | -1.43% |
| 2013 | 119.21 Billion KRW | 3.24% |
| 2012 | 115.46 Billion KRW | -3.27% |
| 2011 | 119.37 Billion KRW | 23.03% |
| 2010 | 97.02 Billion KRW | 7.78% |
| 2009 | 90.02 Billion KRW | 116.75% |
| 2008 | 41.53 Billion KRW | 23.54% |
| 2007 | 33.62 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 153.94 Billion KRW | 6.3% |
| 2024 Q1 | 144.81 Billion KRW | -2.01% |
| 2023 Q2 | 140.32 Billion KRW | 2.74% |
| 2023 FY | 147.79 Billion KRW | 9.33% |
| 2023 Q1 | 136.58 Billion KRW | 1.04% |
| 2023 Q4 | 147.79 Billion KRW | 3.26% |
| 2023 Q3 | 143.13 Billion KRW | 2.0% |
| 2022 Q2 | 133.01 Billion KRW | -2.62% |
| 2022 Q4 | 135.18 Billion KRW | 0.48% |
| 2022 Q1 | 136.58 Billion KRW | -0.58% |
| 2022 FY | 135.18 Billion KRW | -1.61% |
| 2022 Q3 | 134.53 Billion KRW | 1.14% |
| 2021 Q1 | 148.96 Billion KRW | -2.15% |
| 2021 Q2 | 140.43 Billion KRW | -5.73% |
| 2021 FY | 137.38 Billion KRW | -9.76% |
| 2021 Q4 | 137.38 Billion KRW | -0.08% |
| 2021 Q3 | 137.49 Billion KRW | -2.09% |
| 2020 FY | 152.25 Billion KRW | -17.37% |
| 2020 Q1 | 183.47 Billion KRW | -0.42% |
| 2020 Q4 | 152.25 Billion KRW | -7.53% |
| 2020 Q3 | 164.65 Billion KRW | -6.44% |
| 2020 Q2 | 175.99 Billion KRW | -4.08% |
| 2019 Q1 | 163.73 Billion KRW | 9.16% |
| 2019 Q4 | 184.24 Billion KRW | 7.3% |
| 2019 Q3 | 171.71 Billion KRW | 1.95% |
| 2019 Q2 | 168.43 Billion KRW | 2.87% |
| 2019 FY | 184.24 Billion KRW | 22.83% |
| 2018 Q1 | 145.04 Billion KRW | 8.77% |
| 2018 Q3 | 148.51 Billion KRW | 5.14% |
| 2018 Q4 | 150 Billion KRW | 1.0% |
| 2018 FY | 150 Billion KRW | 12.48% |
| 2018 Q2 | 141.25 Billion KRW | -2.61% |
| 2017 Q4 | 133.35 Billion KRW | 9.73% |
| 2017 Q3 | 121.52 Billion KRW | 0.22% |
| 2017 Q2 | 121.25 Billion KRW | -1.09% |
| 2017 Q1 | 122.58 Billion KRW | -3.01% |
| 2017 FY | 133.35 Billion KRW | 5.51% |
| 2016 FY | 126.39 Billion KRW | -4.46% |
| 2016 Q1 | 134.63 Billion KRW | 1.77% |
| 2016 Q2 | 130.52 Billion KRW | -3.05% |
| 2016 Q3 | 121.97 Billion KRW | -6.55% |
| 2016 Q4 | 126.39 Billion KRW | 3.62% |
| 2015 Q1 | 122.41 Billion KRW | 4.18% |
| 2015 Q2 | 121.62 Billion KRW | -0.65% |
| 2015 Q4 | 132.29 Billion KRW | 10.29% |
| 2015 FY | 132.29 Billion KRW | 12.59% |
| 2015 Q3 | 119.95 Billion KRW | -1.37% |
| 2014 Q2 | 117.18 Billion KRW | -1.75% |
| 2014 FY | 117.5 Billion KRW | -1.43% |
| 2014 Q4 | 117.5 Billion KRW | 4.4% |
| 2014 Q3 | 112.55 Billion KRW | -3.94% |
| 2014 Q1 | 119.26 Billion KRW | 0.04% |
| 2013 Q1 | 119.94 Billion KRW | 3.88% |
| 2013 Q3 | 118.94 Billion KRW | -2.68% |
| 2013 Q4 | 119.21 Billion KRW | 0.23% |
| 2013 FY | 119.21 Billion KRW | 3.24% |
| 2013 Q2 | 122.22 Billion KRW | 1.9% |
| 2012 Q4 | 115.46 Billion KRW | 0.0% |
| 2012 Q1 | 90.27 Billion KRW | 0.0% |
| 2012 FY | 115.46 Billion KRW | -3.27% |
| 2011 FY | 119.37 Billion KRW | 23.03% |
| 2011 Q3 | 88.2 Billion KRW | 2.72% |
| 2011 Q2 | 85.86 Billion KRW | -9.42% |
| 2011 Q1 | 94.79 Billion KRW | 0.0% |
| 2010 Q2 | 58.57 Billion KRW | -2.86% |
| 2010 Q1 | 60.29 Billion KRW | 0.0% |
| 2010 Q3 | 61.76 Billion KRW | 5.44% |
| 2010 FY | 97.02 Billion KRW | 7.78% |
| 2009 Q1 | 46.74 Billion KRW | 12.54% |
| 2009 FY | 90.02 Billion KRW | 116.75% |
| 2009 Q3 | 60.56 Billion KRW | 6.55% |
| 2009 Q2 | 56.83 Billion KRW | 21.6% |
| 2008 Q2 | 35.64 Billion KRW | 0.0% |
| 2008 Q3 | 32.59 Billion KRW | -8.54% |
| 2008 FY | 41.53 Billion KRW | 23.54% |
| 2008 Q4 | 41.53 Billion KRW | 27.4% |
| 2007 FY | 33.62 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -89.826% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 84.105% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 79.098% |
| HANDOK Inc. | 449.7 Billion KRW | 67.135% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -72.515% |
| Yuhan Corporation | 712.33 Billion KRW | 79.252% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 76.612% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -829.846% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 82.65% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -176.103% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 28.212% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -96.611% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -109.931% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -89.826% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -305.624% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 41.153% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 33.035% |
| JW Holdings Corporation | 827.51 Billion KRW | 82.14% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 66.179% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 74.813% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 61.066% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -86.37% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -111.232% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 39.142% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 55.254% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -89.826% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 69.839% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 82.775% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 61.066% |
| Yuhan Corporation | 712.33 Billion KRW | 79.252% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 69.068% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -7.904% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 71.395% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 61.066% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 4.363% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -64.279% |
| CKD Bio Corp. | 170.76 Billion KRW | 13.449% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 39.362% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 6.256% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -243.555% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -86.37% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 76.634% |
| Boryung Corporation | 373.1 Billion KRW | 60.388% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 29.012% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 28.212% |
| JW Lifescience Corporation | 96.44 Billion KRW | -53.245% |